comprehensive -WSS

comprehensive

author：leisure time 2025-09-02 08:14:29 - browse：92763

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： A new crop of companies is reshaping the health data economy

WSS

Heart disease in astronauts blamed on cosmic radiation

Biden warns of ‘dark winter’ during final presidental debate

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Study links childhood stress with decline in older age

Late stage cancers on the rise after pandemic delayed screenings

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Medical leaders decry Supreme Court decision on affirmative action

What it's like to live with paralysis for one psychologist

New air purifier tech could be key to improving indoor air quality

Study links childhood stress with decline in older age

Jerome Adams on the need for new antivirals for Covid

Democrats decry new health bill for going easy on private equity

Activists slam private health insurers over coverage restrictions

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Heart attack and stroke risk calculators need revising

Why patients can’t get everything they want on drug pricing

explore

A controversial new treatment promises to make little people taller

Former reverend arrested for allegedly killing 8

Truvian presents data for its desktop blood

When waiting feels immoral: Empathy in the emergency department

Rise in cancer among younger people worries and puzzles doctors

Truvian presents data for its desktop blood

focus

focus

hotspot

entertainment